Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EXPRESSION OF C-MPL MESSENGER-RNA, THE RECEPTOR FOR THROMBOPOIETIN, IN ACUTE MYELOID-LEUKEMIA BLASTS IDENTIFIES A GROUP OF PATIENTS WITH POOR RESPONSE TO INTENSIVE CHEMOTHERAPY
Autore:
WETZLER M; BAER MR; BERNSTEIN SH; BLUMENSON L; STEWART C; BARCOS M; MROZEK K; BLOCK AMW; HERZIG GP; BLOOMFIELD CD;
Indirizzi:
ROSWELL PK CANC INST,DIV MED,DEPT HEMATOL ONCOL,CYTOGENET RES LAB,ELM& CARLTON STS BUFFALO NY 14263 ROSWELL PK CANC INST,DIV MED,DEPT BONE MARROW TRANSPLANTAT,CYTOGENET RES LAB BUFFALO NY 14263 ROSWELL PK CANC INST,LAB FLOW CYTOMETRY BUFFALO NY 14263 ROSWELL PK CANC INST,CLIN CYTOGENET LAB BUFFALO NY 14263 ROSWELL PK CANC INST,DIV PATHOL BUFFALO NY 14263
Titolo Testata:
Journal of clinical oncology
fascicolo: 6, volume: 15, anno: 1997,
pagine: 2262 - 2268
SICI:
0732-183X(1997)15:6<2262:EOCMTR>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; BREAST-CANCER; MOLECULAR-CLONING; PROGNOSTIC VALUE; PROTO-ONCOGENE; NEU ONCOGENE; LIGAND; GENE; MEGAKARYOCYTOPOIESIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
51
Recensione:
Indirizzi per estratti:
Citazione:
M. Wetzler et al., "EXPRESSION OF C-MPL MESSENGER-RNA, THE RECEPTOR FOR THROMBOPOIETIN, IN ACUTE MYELOID-LEUKEMIA BLASTS IDENTIFIES A GROUP OF PATIENTS WITH POOR RESPONSE TO INTENSIVE CHEMOTHERAPY", Journal of clinical oncology, 15(6), 1997, pp. 2262-2268

Abstract

Purpose: c-mpl, the human homolog of v-mpl, is the receptor for thrombopoietin. Given that c-mpl expression carries an adverse prognosis inmyelodysplastic syndrome and given the prognostic significance of expression of other growth factor receptors in other diseases, we attempted to determine whether c-mpl mRNA expression is a prognostic factor in acute myeloid leukemia (AML). Patients and Methods: We analyzed bonemarrow samples from 45 newly diagnosed AML patients by reverse-transcription polymerase chain reaction. Results: Samples from 27 patients (60%) expressed c-mpl mRNA (c-mpl(+)); their clinical and laboratory features were compared with those of the 18 patients without detectable levels of c-mpl (c-mpl(-)). No significant differences in age, sex, leukocyte count, French-American-British subtype, or karyotype group were found. c-mpl(+) patients more commonly find secondary AML (41% v 11%; P = .046) and more commonly expressed CD34 (67% v 12%; P = .0004). There was no significant difference in complete remission (CR) rate. However, c-mpl(+) patients had shorter CR durations (P = .008; median, 6.0 v > 17.0 months). This was true when only de novo AML patients wereconsidered and when controlling for age, cytogenetics, or CD34 expression. There was a trend toward shorter survival in c-mpl(+) patients (P = .058; median, 7.8 v 9.0 months). Conclusion: These data suggest that c-mpl expression is an adverse prognostic factor for treatment outcome in adult AML that must be considered in the analysis of clinical studies using thrombopoietin in AML. (C) 1997 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:07:27